These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23242248)

  • 21. Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.
    Gennigens C; De Cuypere M; Seidel L; Hermesse J; Barbeaux A; Forget F; Albert A; Jerusalem G; Kridelka F
    Cancer Med; 2020 Nov; 9(22):8432-8443. PubMed ID: 32954675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current methods of chemoradiotherapy for locally advanced cervical cancer. Options for reduction of side-effects].
    Póti Z; Mayer A
    Orv Hetil; 2013 May; 154(21):803-9. PubMed ID: 23692874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.
    Vandecasteele K; Tummers P; Makar A; van Eijkeren M; Delrue L; Denys H; Lambert B; Beerens AS; Van den Broecke R; Lambein K; Fonteyne V; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):408-14. PubMed ID: 22377596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
    Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
    Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
    Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
    BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
    Rose PG; Sill MW; McMeekin DS; Ahmed A; Salani R; Yamada SD; Wolfson AH; Fusco N; Fracasso PM
    Gynecol Oncol; 2012 Apr; 125(1):158-62. PubMed ID: 22198338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.
    Einstein MH; Ndlovu N; Lee J; Stier EA; Kotzen J; Garg M; Whitney K; Lensing SY; Tunmer M; Kadzatsa W; Palefsky J; Krown SE
    Gynecol Oncol; 2019 Apr; 153(1):20-25. PubMed ID: 30773222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Zhu H; Zakeri K; Vaida F; Carmona R; Dadachanji KK; Bair R; Aydogan B; Hasan Y; Yashar CM; Mell LK
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):386-93; quiz 394. PubMed ID: 25828068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer: a meta-analysis result.
    Hu Y; Cai ZQ; Su XY
    Asian Pac J Cancer Prev; 2012; 13(9):4301-4. PubMed ID: 23167332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116.
    Small W; Winter K; Levenback C; Iyer R; Gaffney D; Asbell S; Erickson B; Jhingran A; Greven K
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1081-7. PubMed ID: 17398031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy.
    Noticewala SS; Li N; Williamson CW; Hoh CK; Shen H; McHale MT; Saenz CC; Einck J; Plaxe S; Vaida F; Yashar CM; Mell LK
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):797-805. PubMed ID: 28244416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer.
    Abu-Rustum NR; Lee S; Correa A; Massad LS
    Gynecol Oncol; 2001 Apr; 81(1):88-91. PubMed ID: 11277656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
    Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis.
    Liu X; Wang W; Meng Q; Zhang F; Hu K
    Jpn J Clin Oncol; 2019 Mar; 49(3):263-269. PubMed ID: 30668725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The volume of
    Wang SB; Liu JP; Lei KJ; Jia YM; Xu Y; Rong JF; Wang CX
    Cancer Med; 2019 Dec; 8(17):7219-7226. PubMed ID: 31621208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.